Stand Up To Cancer® (SU2C) raises awareness and funds research to detect and treat cancers with the aspiration to cure all patients.
SU2C is a 501(c)(3) charitable organization and was initially launched in 2008 as a division of the Entertainment Industry Foundation. Established by media and entertainment leaders, SU2C utilizes these communities’ resources to engage the public in supporting a collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. The American Association for Cancer Research is SU2C’s scientific partner.
Lily, survivor
DEAR FRIENDS,
It is with deep gratitude and pride that I share SU2C’s 2024 annual report with you. This year, you took a stand against cancer with us, and your support made a profound impact on our shared goal of ending cancer as we know it.
2024 was a pivotal year for SU2C. Building on the exceptional pace of research to date, we further refined our research strategy with a key focus on early-stage detection and cancer interception. With the growing promise of immunotherapies, liquid biopsy cancer screenings, anticancer vaccines, and other critical advances, we now have more ways to catch cancer earlier and treat it more effectively, meaning millions more lives saved.
In this year’s report, you’ll discover how our organization made remarkable progress as a direct result of your support. Our two innovation summits brought together leaders with expertise in artificial intelligence (AI) as well as preventive and therapeutic vaccines to discuss new possibilities for cancer research and treatment. We also continued to forge a bold path forward with critical funding in 2024 for breast, gastroesophageal, pancreatic, pediatric, and rectal cancers, as well as sarcoma and other important areas of focus. We continue to evolve as science evolves.
When we stand against cancer, we do it together. This year, SU2C’s awareness efforts and collaborations with the entertainment and sports communities reached millions of people, reinforcing the importance of cancer research and promoting early-stage detection through cancer screenings. Private funding for scientific research is more critical today than ever, and it will take all of us to realize the possibilities ahead.
Our community is extraordinary, embodying the power of collaboration and our shared commitment to high-impact science. This year, we were delighted to welcome new experts to our Scientific Advisory Committee who will play an important role in guiding our scientific strategy.
I am grateful to you for standing with us. Thanks to our donors, collaborators, and our longstanding partner, the American Association for Cancer Research, we have made great strides. On behalf of all of us at SU2C, and our SU2C-funded research teams making life-saving discoveries around the world, thank you for supporting our mission.
We are truly stronger together.
Warmly,
Julian Adams, Ph.D. President and CEO
INNOVATION TOGETHER, WE FUELED
2024 was a year of considerable progress in cancer research. We hosted our annual SU2C Scientific Summit and two crucial innovation summits. These events reflected our core goal of fostering collaboration, catalyzed important conversations about our scientific strategy, and helped us set a bold agenda for the future.
2024 SU2C Summits
Since SU2C’s inception, our collaboration with the AACR has been instrumental to our progress. As SU2C’s trusted scientific partner, AACR plays a vital role in administering select SU2C-funded research teams and supporting our annual Scientific Summit, which brings together leading cancer experts from around the world. AACR also works closely with SU2C’s Scientific Advisory Committee to support our rigorous review process, helping to identify the most promising research proposals with the greatest potential to drive advances in cancer treatment and prevention. This synergistic relationship between SU2C and AACR helps propel both organizations’ shared mission to end cancer.
SU2C Scientific Summit 2024
JANUARY 26-29, 2024 | CORONADO, CA
SU2C’s 15th annual Scientific Summit, organized with support from AACR, combined collaboration and celebration along with deep appreciation for our researchers’ critical work. The event inspired and motivated our 300 Summit participants, including SU2C’s dedicated donors and patient advocates, and showcased our positive impact on patient outcomes. During the Scientific Summit, several new AACR-administered grants were awarded, including the Cless Family Gastric Cancer Innovation in Collaboration Award and two Phillip A. Sharp Innovation in Collaboration Awards.
BREAKTHROUGHS TOGETHER, WE DROVE
Our Year in Science
Our two innovation summits featured emerging possibilities in cancer research, such as harnessing the significant potential of AI as well as the potential of therapeutic vaccines.
AI in Cancer Research, Diagnosis, and Treatment
MAY 3, 2024 | MOUNTAIN VIEW, CA
AI and machine learning are significantly enhancing clinicians’ ability to detect and treat cancer at earlier stages. At our first Innovation Summit of 2024, we convened 83 leading researchers, clinicians, and collaborators to discuss innovative work taking place today and define our vision for the future.
Detection Platforms and Vaccines
NOVEMBER 3, 2024 | NEW YORK, NY
Early detection and anti-cancer vaccines hold substantial life-saving potential. If detected early, 90% of cancers are curable with current treatments. Vaccines provide further possibilities to prevent and treat cancers in the adjuvant setting. This combination strategy was the subject of our second Innovation Summit, where 90 experts came together to create a roadmap for these new frontiers.
MARY’S STORY
For five years, Mary shuffled from doctor to doctor seeking help for a lump in the soft tissue of her knee. Repeatedly misdiagnosed as a lipoma (a benign, fatty tissue growth), the lump continued to grow. Mary was initially referred to a surgeon to have it removed for cosmetic reasons, but after her consultation, she chose to delay surgery. When she returned to the surgeon, the bump had changed and she was sent for imaging. Scans revealed that the lump was actually stage 3 sarcoma: an aggressive soft tissue cancer. Mary was referred to a sarcoma specialist at the University of Michigan who offered her a place in Dr. Kirsch’s SU2C Catalyst® team’s immunotherapy clinical trial. Mary completed her last dose of immunotherapy in June 2020 and is still cancer-free today.
Groundbreaking Clinical Trial
Novel immunotherapy for soft-tissue sarcoma
For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, rare cancers that affect muscles, fat, and other connective tissues. A SU2C Catalyst Research Team comprising researchers from around the world announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults. The study, led by David Kirsch, M.D., Ph.D., enrolled 127 patients across 20 hospitals in four countries. It introduced a new regimen of sarcoma care including the immunotherapy drug pembrolizumab (Keytruda) before, during, and after radiation therapy, and then again after surgery, which the team believed would enhance surgery’s efficacy and prevent recurrence. They were correct. This breakthrough study revealed that the use of immunotherapies reduced the risk of sarcoma relapse by 43% two years following treatment.
I truly believe that [my SU2C-supported clinical trial] saved my life. If people are offered a clinical study, I hope they agree to be in it because it does offer hope.”
Research Breakthrough
First-of-its-kind clinical trial eliminated or shrunk melanoma tumors in 70% of patients
Melanoma is the fifth most common cancer in the U.S., with 100,000 people diagnosed each year. A SU2C Catalyst Research Team tested a novel combination of immunotherapy and targeted therapy before and after surgery for melanoma, with noteworthy results. “We saw about two-thirds of the patients in one arm of the study had no remaining tumor at all at the time of their surgery,” said lead investigator Matthew S. Block, M.D., Ph.D. Trial results were published in Nature Communications on February 16.
Defining the Moment in Cancer Research
New Publication by SU2C Science Team
While cancer was once considered the “Emperor of All Maladies,” the acceleration of cancer research and treatment in the 20th and 21st centuries is unprecedented, pointing the way to a more hopeful future. The SU2C Science Team reflected on this trajectory and the still-greater possibilities for the future in a new publication titled “Cancer Treatment: Advances in the 21st Century and Beyond,” published in the Drug Information Association Global Forum digital magazine on April 6, 2024.
You are invited to read the publication at SU2C.org/CancerAdvances.
KELLY’S STORY
Shortly after giving birth to a healthy baby boy in 2019, Kelly began experiencing worrying symptoms. After several misdiagnoses, a colonoscopy revealed that she had stage 3 rectal cancer. She was told her treatment protocol would include chemotherapy, radiation, and surgery, and that the after-effects of these treatments meant that she would most likely not be able to get pregnant again.
When Kelly reached out to schedule her first chemo appointment, a research nurse told her about an immunotherapy clinical trial led by SU2C’s Colorectal Cancer Dream Team. After just nine treatments, Kelly’s tumor had completely disappeared. She is still in remission today and enjoying her growing family: in 2023, she and her husband celebrated the birth of their daughter, Maya, and they are expecting their third child in May 2025.
Gunther, survivor
Without SU2C, my life wouldn’t look the way it does now. I wouldn’t have [my daughter] Maya or be waiting for baby number three. I’ll never win the lottery because I already have.”
New Science Funding in 2024
In 2024, SU2C provided new research grants, from foundational science that answers critical questions about cancer biology to clinical trials that test novel combination therapies. Our focus on big ideas and crossinstitutional collaboration advances the most promising work and helps get new treatments to patients faster.
New Funding Spotlight
New SU2C Catalyst grant for AL amyloidosis research
In November 2024, SU2C announced a new collaboration with Johnson & Johnson focused on AL amyloidosis, a rare disease associated with blood cancers such as multiple myeloma, lymphoma, and chronic lymphocytic leukemia. Investigators participating in this effort via a SU2C Catalyst grant will explore a novel combination of two targeted therapies, teclistamab and daratumumab, for the treatment of AL amyloidosis.
Continued Funding
SU2C-CRUK Pediatric Cancer New Discoveries Challenge
PROJECT TITLE: Combinatorial Targeting of Oncogene-Driven Childhood Cancer
LEADER: John Anderson, MBBS, MRCP, Ph.D., University College London, Great Ormond Street Institute of Child Health
CO-LEADER: Louis Chesler, M.D., Ph.D., Institute of Cancer Research
SU2C-CRUK Pediatric Cancer New Discoveries Challenge
PROJECT TITLE: BRAINatomy: A Validated Anatomical Atlas of Childhood Neuroradiation Damage
LEADER: Martin McCabe, MB/BChir, Ph.D., University of Manchester
CO-LEADER: Thomas Merchant, D.O., Ph.D., St. Jude Children’s Research Hospital
SU2C’s long-standing strategic partnership with Cancer Research UK (CRUK) involves jointly funding international research, partially supported by CRUK through its Stand Up To Cancer campaign in the United Kingdom.
New Funding
Ziskin Prize 2024
PROJECT TITLE: Improving Triple Negative Breast Cancer (TNBC) Patient Outcome with Personalized PARP Inhibitor-Based Combination Therapy
LEADER: Marilyne Labrie, Ph.D., Université de Sherbrooke
CO-LEADER: Funda Meric-Bernstam, M.D., UT MD Anderson Cancer Center
SU2C Nina Nicolai Pancreatic Cancer Innovation in Collaboration Award
PROJECT TITLE: Understanding How KRAS Inhibition Reshapes the Antigen Landscape in Pacreatic Cancer
LEADER: William Freed-Pastor, M.D., Ph.D., Dana-Farber Cancer Institute
CO-LEADER: Steven Carr, Ph.D., Broad Institute
Phillip A. Sharp Innovation in Collaboration Award 2024
PROJECT TITLE: Neoadjuvant Immune Checkpoint Blockade in Mismatch Repair Proficient Locally Advanced Rectal Cancer
LEADERS: Andrea Cercek, M.D., and Aparna Parikh, M.D.
LEAD INSTITUTION: Memorial Sloan Kettering Cancer Center
Phillip A. Sharp Innovation in Collaboration Award 2024
LEADERS: Shawn Davidson, Ph.D., and Ami Bhatt, M.D., Ph.D.
LEAD INSTITUTION: Northwestern University
SU2C Catalyst with Support from Merck
PROJECT TITLE: Correlative study for project entitled “Pembrolizumab and Radiation Therapy to Improve Outcome in High-Risk Sarcoma”
LEADER AND INSTITUTION: Everett Moding, M.D., Ph.D., Stanford University
SU2C Convergence – Torrey Coast Foundation Research Team
PROJECT TITLE: Optimal Vaccine Design for Gastric Esophageal Cancer
LEADER: Benjamin Greenbaum, Ph.D., Memorial Sloan Kettering Cancer Center
Cless Family Foundation Gastric Cancer Innovation in Collaboration Award
PROJECT TITLE: Spatial Profiling and Organoids: Immune Co-cultures to Develop Multimodal Predictive Biomarkers for CIN Gastro-esophageal Cancer
LEADERS: Karuna Ganesh, M.D., Ph.D., and Christina Curtis, Ph.D., M.Sc.
LEAD INSTITUTION: Memorial Sloan Kettering Cancer Center
SU2C Convergence – Torrey Coast Foundation Research Team
PROJECT TITLE: Defining the Neoantigen and TCR Landscape to Inform Vaccine Approaches in Gastroesophageal Cancer
LEADER: Gad Getz, Ph.D., Broad Institute
SU2C Maverick Award 2024
PROJECT TITLE: LINE-1 as a Cancer Biomarker, Contributor to Carcinogenesis, and Target for Cancer Chemoprevention
RECIPIENT: Martin Taylor, M.D., Ph.D., Brown University
Dan, survivor
Luke, survivor
Ivy, survivor
Continued Support for Important Research
SU2C Diversity in Early Development Clinical Trials Research Grants Program
PROJECT TITLE: Enhancing Diversity in Early Phase Clinical Trials
LEADER: Martin Edelman, M.D., Fox Chase Cancer Center
PROJECT TITLE: Eliminating Enrollment Barriers to Early Phase Trials in a Diverse Population in Los Angeles County
TEAM LEADER AND INSTITUTION: Anthony El-Khoueiry, M.D., University of Southern California
PROJECT TITLE: Transferring Care to Enhance Access to Early-phase Cancer Clinical Trials
LEADER: David Gerber, M.D., University of Texas Southwestern Medical Center
PROJECT TITLE: Enhancing Diversity in Early Phase Clinical Trials in an Urban Underserved Community
LEADER: Walter Stadler, M.D., University of Chicago
Pancreatic Cancer Collective New Therapies Challenge
PROJECT TITLE: Molecularly Targeted Radionuclide Therapy via the Integrin
LEADER: Julie L. Sutcliffe, Ph.D., University of California at Davis
Photo, left to right: John D. Carpten, Ph.D., Vice Chairperson, Stand Up To Cancer Scientific Advisory Committee, Chairperson, Stand Up To Cancer Health Equity Committee and Arnold J. Levine, Ph.D., Vice Chair, Stand Up To Cancer Scientific Advisory Committee
WE RAISED
OUR VOICES TOGETHER,
Celebrity Ambassadors, Public Awareness, and Media
SU2C’s events, Public Service Announcements (PSAs), and awareness campaigns bring life-saving information and inspiring stories to the public. This year, thousands of cancer survivors, celebrity ambassadors, television networks, corporate supporters, fellow nonprofit organizations, and individuals shared their talents and influence in support of our mission. Leveraging our growing presence in the gaming community and our enduring engagement with the entertainment industry, we elevated new voices and raised national awareness of the importance of cancer research.
Patient Ambassadors
SU2C ran 12 PSAs across $185 million of donated ad space this year. Our PSAs serve a vital role in educating the public about the impact of cancer research and the importance of regular screenings to detect and treat cancer early. They enable us to shine a light on the insights of our researchers and the stories of patients like Kelly Spill whose lives were saved due to their dedicated work.
Celebrity Ambassadors
More than 100 actors, professional athletes, and other celebrities lent their time, voices, and platforms to raise crucial funds to advance cancer research: from Giving Tuesday to special social media initiatives and livestream fundraising events on popular television networks. These networks creatively integrated SU2C’s message into six popular TV shows, including Celebrity Name That Tune, Who Wants to be a Millionaire, The Golden Bachelorette, 9-1-1: Lone Star, Jeopardy!, and Survivor.
Content Creators
In 2024, the #SU2CStreamTeam and creator programs brought together groups of dedicated streamers who have a passion for raising funds and awareness for cancer research. The 4th annual #Up2Us streaming event brought together even more streamers and content creators across platforms to support SU2C’s mission. Additionally, an integrated awareness campaign with Pokémon GO generated millions of in-app impressions, amplifying SU2C’s reach. This year also marked the launch of #UniteAcrossPlatforms, SU2C’s first end-of-year streaming creator event, further solidifying its connection with Gen Z and Millennial audiences in the fight against cancer.
Folasade P. May, M.D., Ph.D., M.Phil.
SU2C Colorectal Cancer Health Equity Dream Team Co-Leader
MILLIONS TOGETHER, WE REACHED
Corporate Collaborations
In 2024, SU2C reached millions of people through our longstanding, strategic collaborations with Major League Baseball (MLB), American Airlines, Mastercard, and other valued supporters. Together with sports fans and players as well as our corporate supporters’ employees, we created highly visible and influential moments that united people in support of cancer research and made an enduring impact.
Drone show at Hudson Yards created by Mastercard.
Major League Baseball
As our founding donor, Major League Baseball and all 30 Clubs have steadfastly supported SU2C’s mission for 17 years. In 2011, MLB and SU2C created the first-ever Placard Moment™ at the MLB All-Star Game. Since then, the placard moments have been a staple of All-Star Games and the World Series, with hundreds of thousands of fans, players, umpires, and stadium staff pausing to honor a loved one affected by cancer. This year’s post-fifth-inning Placard Moment was as moving as ever: while thousands of fans stood with placards held high, survivors took the field with their own placards alongside former All-Stars Derek Jeter, Alex Rodriguez, and David Ortiz. After the All-Star Game, MLB with support from Mastercard, included in their social channels videos featuring MLB players sharing their placards and the names of loved ones they stand up for, as well as longer videos featuring Anthony Rizzo and Liam Hendriks sharing their personal cancer stories.
Mastercard
Since 2010, SU2C has maintained a meaningful collaboration with Mastercard, which runs a successful annual campaign in support of our mission. In 2024, Mastercard produced a moving television spot created by cancer survivors as well as patients still in treatment and others whose lives have been impacted by cancer. Mastercard and SU2C used multiple channels to build awareness and raise funds for cancer research, including taking over the store windows at the New York City Saks Fifth Avenue, claiming a highly visible spot on Times Square video boards, and creating engaging ways for people to share who they stand up for on multiple social media platforms. During the MLB All-Star Game weekend, the campaign culminated in a beautiful and inspiring drone show at Hudson Yards, lighting the night and raising awareness for SU2C’s life-saving mission.
American Airlines
In August, we launched another successful mileage campaign with American Airlines. During this campaign, American team members and customers who donated a minimum of $25 to SU2C received American Airlines AAdvantage® bonus miles for every dollar given. This incentive included moving television spots featuring American team members, SU2C celebrity ambassador Rosario Dawson, and cancer survivor Pearce, who is also a former SU2C intern and patient ambassador and is pictured on the cover of this report.
TAKE YOUR STAND
We are deeply grateful to our committed community of supporters. Time and again, we have seen the powerful ways you come together to advance our mission through heartfelt tribute gifts, inspiring fundraising events, or long-term legacy commitments. We invite you to join us again this year as we continue to push the boundaries of science on behalf of patients with cancer.
Every gift, no matter the size or form, helps accelerate discoveries and brings us closer to cures. Thank you for being part of the SU2C community and for your unwavering support.
Greta, survivor
Cancer research is important to our family because we have lost close family members over the years. While advancements in cancer treatments have been developed over the last 50 years, there is still a long way to go to find a cure for this awful disease.”
— STEVE AND DAVID, Brenda’s husband and son
BRENDA’S LEGACY
When she was diagnosed with cancer, Brenda was given a year or less to live. Instead, she lived for over two years and was able to attend her daughter’s wedding, while participating in clinical trials her doctor found through SU2C. Brenda’s courage inspired her son David to run in the New York half marathon in her honor, and to raise over $20,000 for SU2C, supported by his dad, Steve, and other friends and family. For more information on how you can create your own fundraiser or make a gift in honor of a loved one, visit StandUpToCancer.org/Fundraise.
YOUR GENEROSITY MAKES CANCER RESEARCH BREAKTHROUGHS POSSIBLE.
A Preview of SU2C in 2025
WE’LL KEEP STANDING TOGETHER
As we look to the year ahead, we move forward with the strong conviction that funding early-stage detection is essential to defeating cancer. When cancer is caught early, treatment is substantially more effective, and rates of remission and cure are much higher. We have set a bold goal to make early-stage detection the standard of care for all cancers. With continued investment, we believe it is achievable to reduce cancer deaths by 25% in five years and 50% in ten years.
In 2025, we will continue to move cancer research forward by facilitating scientific collaboration around big ideas, raising crucial research funds, and continuing to expand public awareness and support. Our focus on early-stage detection amplifies the power of our research funding mission, giving patients a head start on their treatment.
Great possibilities are ahead. Liquid biopsies can help bring early-stage cancer detection to millions of people, including medically-underserved communities, thanks to their simplicity and scalability. As AI transforms cancer detection and treatment, we can anticipate earlier diagnoses, more successful treatments, and many more lives saved. Therapeutic vaccines also hold significant promise, with positive results already unfolding in clinical trials. Personalized vaccines for melanoma and lung, colorectal, and pancreatic cancers can treat cancer, strengthen patients’ immune systems, and reduce recurrence.
Among our 2025 scientific and innovation summits will be a dedicated summit with a focus on Translating Data at the Limit of Detection in Cancers, discussing how big data can help detect minimal residual disease and help survivors stay in remission. We will continue to raise awareness and funds through our Telecast, PSAs, and sports and entertainment events alongside our dedicated collaborators. We hope you’ll join us. You are a vital part of our movement.
TOGETHER, WE CAN CREATE A WORLD WITHOUT CANCER.
THANK YOU FOR STANDING WITH US.
I wasn’t supposed to be able to walk or talk after my surgery, let alone graduate high school, move to California for college, or have the opportunity to work at SU2C [as an intern]. As a survivor, I feel a responsibility to be a voice for my friends who didn’t [get these chances], and I will continue to advocate in their honor and memory.”
— PEARCE, survivor and SU2C ambassador
2024 FINANCIALS
REVENUE
1 Value of media donated to SU2C to air public service announcements.
2 In kind contribution of merchandise and services, including airline miles to support its programs.
3 Grant Program expenses are typically spread over several years and may not align with revenue received in any given year. Information reflects unaudited financials. Financial audit in progress at the time of printing. Upon completion, audited financial statements will be available upon request.
EXPENSES
Marshella, survivor
SU2C LEADERSHIP
SU2C envisions a future where every cancer is caught in time to be cured, and where survivors can enjoy life without fear of recurrence.”
BOARD OF DIRECTORS
Sherry Lansing Chair
Jeff Bader
Secretary
Peter Seymour
Treasurer
Russell Chew
Susan Desmond-Hellmann, M.D., M.P.H.
William (Bill) Nelson, M.D., Ph.D.
Phillip A. Sharp, Ph.D.
EXECUTIVE TEAM
Julian Adams, Ph.D.
President and CEO
Shawn Burke
Chief Financial Officer
Dana Hirsch Lipman
General Counsel and
Human Resources
FOUNDERS AND ADVISORS COMITTEE
Katie Couric
Sherry Lansing
Kathleen Lobb
Lisa Paulsen
Rusty Robertson
Sue Schwartz
Pamela Oas Williams
Ellen Ziffren
In Remembrance
Noreen Fraser
Laura Ziskin
SCIENTIFIC ADVISORY COMMITTEE
William G. Nelson, M.D., Ph.D.
Chairperson
Johns Hopkins University
John D. Carpten, Ph.D.
Vice Chairperson
City of Hope National Medical Center
Arnold J. Levine, Ph.D.
Vice Chairperson
Institute for Advanced Study
MEMBERS
Scott A. Armstrong M.D., Ph.D.
Dana-Farber Cancer Institute
Carlos L. Arteaga, M.D.
UTSW Harold C. Simmons Cancer Center
Michael A. Caligiuri, M.D.
City of Hope National Medical Center
Steven Carr, Ph.D.
Broad Institute
Jenny C. Chang, M.D.
Houston Methodist Hospital
Suzanne Dahlberg, Ph.D.
Boston Children’s Hospital
Alan D. D’Andrea, M.D.
Dana-Farber Cancer Institute
Luis A. Diaz, Jr., M.D.
Memorial Sloan Kettering Cancer Center
S. Gail Eckhardt, M.D.
Baylor College of Medicine
MEMBERS continued
Michael Fischbach, Ph.D.
Stanford University
Richard B. Gaynor, M.D.
BioNTech
Nancy F. Goodman, J.D.
Kids v Cancer
James L. Gulley, M.D., Ph.D.
National Cancer Institute
David G. Kirsch, M.D., Ph.D.
Princess Margaret Cancer Centre
Guillermina (Gigi) Lozano, Ph.D.
University of Texas MD Anderson Cancer Center
Tomas J. Philipson, Ph.D.
The University of Chicago
Lecia Sequist, M.D., M.P.H.
Harvard Medical School
Laura K. Shawver, Ph.D.
Capstan Therapeutics
Peter Sorger, Ph.D.
Harvard Medical School
David A. Tuveson, M.D., Ph.D.
Cold Spring Harbor Laboratory Cancer Center
EMERITUS MEMBERS
Elizabeth H. Blackburn, Ph.D.
The University of California, San Francisco
Lisa Diller, M.D.
Dana-Farber Cancer Institute
Judy Garber, M.D., M.P.H.
Dana-Farber Cancer Institute
Laurie H. Glimcher, M.D.
Dana-Farber Cancer Institute
William N. Hait, M.D., Ph.D.
Janssen, Pharmaceutical Companies of Johnson & Johnso
William G. Kaelin, Jr., M.D.
Dana-Farber Cancer Institute
Tak W. Mak, Ph.D.
University of Toronto
Andre Nussenzweig, Ph.D.
National Cancer Institute
Roderic I. Pettigrew, Ph.D., M.D.
Texas A&M University
Cecil B. Pickett, Ph.D. Biogen Inc.
Carol L. Prives, Ph.D.
Columbia University
Phillip A. Sharp, Ph.D.
Massachusetts Institute of Technology
Arlene Sharpe, M.D., Ph.D.
Harvard Medical School
HEALTH EQUITY COMMITTEE
John D. Carpten, Ph.D.
Chairperson City of Hope National Medical Center
Andrew T. Chan, M.D., M.P.H.
Harvard Medical School
Margaret Foli, Ph.D., M.D. (hc)
American Association for Cancer Research
Shawna Hudson, Ph.D.
Rutgers Robert Wood Johnson Medical School
Chanita Hughes-Halbert, Ph.D.
Norris Comprehensive Cancer Center University of Southern California
Elizabeth M. Jaffee, M.D.
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Guillermina (Gigi) Lozano, Ph.D. University of Texas MD Anderson Cancer Center
John Whyte, M.D., M.P.H. WebMD
David R. Wilson, Ph.D. University of North Dakota
Karen M. Winkfield, M.D., Ph.D.
Meharry-Vanderbilt Alliance
Robert A. Winn, M.D.
Massey Cancer Center,
Virginia Commonwealth University
THANK YOU TO OUR GENEROUS SUPPORTERS
LUMINARIES
Bristol Myers Squibb
Genentech
Lustgarten Foundation
Major League Baseball - Founding Donor
Mastercard
VISIONARIES
American Airlines
HEROES
Cancer Research UK
Exact Sciences
Merck
Torrey Coast Foundation
Van Andel Institute
SU2C is grateful for the support of our committed donors, from corporations and industry to scientists and experts to dedicated philanthropists and family foundations. Many different sectors have joined us as crucial collaborators in advancing cancer research. It takes all of us, standing together, to succeed.
